89bio, Inc. Banner Image

89bio, Inc.

  • Ticker ETNB
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
89bio, Inc. Logo Image
  • 11-50 Employees
  • Based in San Francisco, California
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is being developed for the treatment of NASH and for the treatment of SHTG. BIO89-100 is a specifically engineered glycoPEGylated analog of FGF21 that is currentlyMore in a proof of concept Phase 1b/2a clinical trial in patients with NASH or NAFLD and a high risk of NASH and a Phase 2 trial in patients with SHTG is expected to initiate shortly. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
4.8 / 5.0 (170)

89bio, Inc. reports have an aggregate usefulness score of 4.8 based on 170 reviews.

89bio, Inc.

Most Recent Annual Report

89bio, Inc.
MOST RECENT 2023 Annual Report and Form 10K

Older/Archived Annual Reports

89bio, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!